Cargando…

Long-acting antiretrovirals: a new era for the management and prevention of HIV infection

The long-acting antiretroviral cabotegravir and rilpivirine combination has just received FDA, EMA and Health Canada approval. This novel drug delivery approach is about to revolutionize the therapy of people living with HIV, decreasing the 365 daily pill burden to only six intramuscular injections...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thoueille, Paul, Choong, Eva, Cavassini, Matthias, Buclin, Thierry, Decosterd, Laurent A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809192/ https://www.ncbi.nlm.nih.gov/pubmed/34499731 http://dx.doi.org/10.1093/jac/dkab324

Ejemplares similares

Development and validation of a multiplex UHPLC‐MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration
por: Thoueille, Paul, et al.
Publicado: (2023)

Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
por: Courlet, Perrine, et al.
Publicado: (2021)

Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland
por: Thoueille, Paul, et al.
Publicado: (2022)

Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study
por: Thoueille, Paul, et al.
Publicado: (2023)

Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV
por: Courlet, Perrine, et al.
Publicado: (2019)

Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers
por: Dao, Kim, et al.
Publicado: (2020)

Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Long-acting injectable antiretrovirals for HIV treatment and prevention
por: Spreen, William R., et al.
Publicado: (2013)

Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention
por: Kim, Yeon-Sook
Publicado: (2021)

A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
por: Bares, Sara H., et al.
Publicado: (2022)

Injectable long acting antiretroviral for HIV treatment and prevention: perspectives of potential users
por: Slama, Laurence, et al.
Publicado: (2023)

The only way is up: priorities for implementing long-acting antiretrovirals for HIV prevention and treatment
por: Castor, Delivette, et al.
Publicado: (2020)

Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy
por: Barceló, Catalina, et al.
Publicado: (2020)

Therapeutic drug monitoring of cefepime in a non-critically ill population: retrospective assessment and potential role for model-based dosing
por: Suttels, Véronique, et al.
Publicado: (2022)

Valproate in status epilepticus: Correlation between loading dose, serum levels, and clinical response
por: Vijiala, Sergiu, et al.
Publicado: (2022)

The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib
por: Buclin, Thierry, et al.
Publicado: (2020)

Prevention strategies for blood‐borne viruses—in the Era of vaccines, direct acting antivirals and antiretroviral therapy
por: Pfaender, Stephanie, et al.
Publicado: (2016)

Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment?
por: Brizzi, Marisa, et al.
Publicado: (2023)

Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV
por: Zondo, Nomusa M., et al.
Publicado: (2022)

344. HIV and Diabetes in the Era of Antiretroviral Therapy
por: Sabbaj. Spieler, Gabriel, et al.
Publicado: (2019)

Primary or secondary prevention of HIV-associated histoplasmosis during the early antiretrovirals for all era
por: Nacher, Mathieu, et al.
Publicado: (2023)

Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy
por: Buclin, Thierry, et al.
Publicado: (2011)

Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy
por: Cohen, Myron S, et al.
Publicado: (2019)

Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients
por: Perrottet, Nancy, et al.
Publicado: (2010)

Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective
por: Briki, Myriam, et al.
Publicado: (2023)

HIV‐infected patients' beliefs about their chronic co‐treatments in comparison with their combined antiretroviral therapy
por: Kamal, S, et al.
Publicado: (2017)

Residual Antimalarials in Malaria Patients from Tanzania – Implications on Drug Efficacy Assessment and Spread of Parasite Resistance
por: Hodel, Eva Maria, et al.
Publicado: (2009)

Managing HIV/hepatitis C co-infection in the era of direct acting antivirals
por: Rockstroh, Jürgen K, et al.
Publicado: (2013)

Long-Acting HIV Treatment and Prevention: Closer to the Threshold
por: Barnhart, Matthew
Publicado: (2017)

Assessing readiness to implement long-acting injectable HIV antiretroviral therapy: provider and staff perspectives
por: Koester, Kimberly A., et al.
Publicado: (2023)

AIDS defining opportunistic infections in patients with high CD4 counts in the combination antiretroviral therapy (cART) era: things ain't what they used to be
por: Gisler, Valentin, et al.
Publicado: (2014)

HIV-associated wasting prevalence in the era of modern antiretroviral therapy
por: Siddiqui, Javeed, et al.
Publicado: (2022)

HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral Therapy
por: Castelli, Roberto, et al.
Publicado: (2020)

The Interaction of HIV With Mental Health in the Modern Antiretroviral Therapy Era
por: Carrico, Adam W., et al.
Publicado: (2022)

Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals
por: Shilaih, Mohaned, et al.
Publicado: (2017)

Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages
por: Araínga, Mariluz, et al.
Publicado: (2015)

Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy
por: Benning, Lorie, et al.
Publicado: (2020)

Preference for daily oral pills over long-acting antiretroviral therapy options among people with HIV
por: Barthold, Douglas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t1b866dfle796opeeugo0n0o2o